European Medicines Agency advises of risk of fever in young children following vaccination with Pandemrix
2. For more details on the recommended changes, please refer to the updated product information for Pandemrix: http://www.emea.europa.eu/influenza/vaccines/pandemrix/pandemrix_pi.html
3. More information on adverse reactions reported with centrally authorised pandemic vaccines is provided in the weekly pandemic influenza pharmacovigilance update report: http://www.emea.europa.eu/influenza/updates.html
4. More information on the Agency's activities in relation to the influenza pandemic can be found on the Agency's pandemic influenza website: http://www.emea.europa.eu/influenza/home.htm
5. This press release, together with other information on the work of the European Medicines Agency, can be found on the Agency's website: www.emea.europa.eu